LUNG CANCER

LUNG CANCER Journal

publication venue for

Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study 2023
Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study 2022
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. 136:52-56. 2019
High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. 126:48-54. 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting 2018
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. 117:38-43. 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. 117:44-49. 2018
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. 112:195-199. 2017
An open-label, phase II study of the polo-like kinase-1 (P1k-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). 104:126-130. 2017
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. 86:288-290. 2014
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. 83:300-301. 2014
Thoracic tumor effects on plasmatic coagulation: Role of hemeoxygenase-1. 83:288-291. 2014
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. 78:276-281. 2012
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials. 76:222-227. 2012
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. 71:151-155. 2011
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. 70:340-346. 2010
Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. 56:377-381. 2007
Women and lung cancer: Epidemiology, tumor biology, and emerging trends in clinical research 2007
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. 52:305-311. 2006
Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. 52:67-74. 2006
Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. 51:237-243. 2006
Seeking new options for the treatment of small-cell lung cancer. 50:S25-S26. 2005
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. 47:413-419. 2005
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. 47:253-259. 2005
A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. 44:111-119. 2004
Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. 40:91-97. 2003

category

ONCOLOGY Web of Science Category
RESPIRATORY SYSTEM Web of Science Category

International Standard Serial Number (ISSN)

0169-5002

Electronic International Standard Serial Number (EISSN)

1872-8332

journal abbreviation

LUNG CANCER
LUNG CANCER-J IASLC